Exhibit 99.1

Thank you Innovative Biopharmaceuticals CORPORATE PRESENTATION November 2017

Forward - Looking Statements and Kitov’s Safe Harbor Statement Ϯ This presentation is not a prospectus or offer of securities for subscription or sale in any jurisdiction . Certain statements in this presentation are forward - looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and other applicable securities laws . Forward - looking statements can be identified by the use of forward - looking words such as “believe”, “expect”, “intend”, “plan”, “may”, “should”, “could”, “might”, “seek”, “target”, “will”, “project”, “forecast”, “continue” or “anticipate” or their negatives or variations of these words or other comparable words or by the fact that these statements do not relate strictly to historical matters . You should not place undue reliance on these forward - looking statements, which are not guarantees of future performance . Forward - looking statements reflect our current views, expectations, beliefs or intentions with respect to future events, and are subject to a number of assumptions, involve known and unknown risks, many of which are beyond our control, as well as uncertainties and other factors that may cause our actual results, performance or achievements to be significantly different from any future results, performance or achievements expressed or implied by the forward - looking statements . Important factors that could cause or contribute to such differences include, among others, risks relating to : the fact that drug development and commercialization involves a lengthy and expensive process with uncertain outcomes ; our ability to successfully acquire, develop or commercialize our pharmaceutical products ; the expense, length, progress and results of any clinical trials ; the lack of sufficient funding to finance the clinical trials ; the impact of any changes in regulation and legislation that could affect the pharmaceutical industry ; the difficulty in receiving the regulatory approvals necessary in order to commercialize our products ; the difficulty of predicting actions of the U . S . Food and Drug Administration or any other applicable regulator of pharmaceutical products ; the regulatory environment and changes in the health policies and regimes in the countries in which we operate ; the uncertainty surrounding the actual market reception to our pharmaceutical products once cleared for marketing in a particular market ; the introduction of competing products ; patents attained by competitors ; dependence on the effectiveness of our patents and other protections for innovative products ; our ability to obtain, maintain and defend issued patents with protective claims ; the commencement of any patent interference or infringement action ; our ability to prevail, obtain a favorable decision or recover damages in any such action ; and the exposure to litigation, including patent litigation, and/or regulatory actions ; the uncertainty surrounding an investigation by the Israel Securities Authority into our historical public disclosures and the potential impact of such investigation on the trading of our securities or on our clinical, commercial and other business relationships, or on receiving the regulatory approvals necessary in order to commercialize our products, and other factors that are discussed in our Annual Report on Form 20 - F for the year ended December 31 , 2016 and in our other filings with the SEC, including our cautionary discussion of risks and uncertainties under “Risk Factors” in our Registration Statements and Annual Reports . These are factors that we believe could cause our actual results to differ materially from expected results . Other factors besides those we have listed could also adversely affect us . Any forward - looking statement in this press release speaks only as of the date which it is made . We disclaim any intention or obligation to publicly update or revise any forward - looking statement, or other information contained herein, whether as a result of new information, future events or otherwise, except as required by applicable law . You are advised, however, to consult any additional disclosures we make in our reports to the SEC, which are available on the SEC’s website, http : //www . sec . gov .

Company Profile • Founded in 2010 ; publicly traded on TASE 2013 ; IPO on NASDAQ in November 2015 • Tickers: KTOV (ADSs); KTOVW (Warrants) • Cash on hand (as of October 31 , 2017 ): $ ϴ .6 M; no debt • Market Cap: $ 27 M * • Issued & outstanding capital equivalent to 1 ϭ .2 million ADSs ** ϯ PROVEN TEAM • KIT - 302 manufacturing and CMC work partnered with Dexcel Pharma, Israel’s largest private pharmaceutical company • Management team with proven track record in drug development, NDA submissions and FDA approvals * As of November 27 , 2017 ** Each ADS = 20 ordinary shares Innovative Biopharmaceutical Company Leveraging Deep Regulatory and Drug Development Expertise COMPELLING VALUE • Lead drug candidate KIT - 302 developed to treat osteoarthritic pain and hypertension • KIT - 302 NDA filed with FDA; assigned PDUFA date: May 31 , 2018 • NT - 219 – small molecule designed to overcome cancer drug resistance DIVERSE PIPELINE ADDRESSING LARGE MARKETS

Experienced Management ϰ Paul Waymack, M.D., Sc.D. Chairman of the Board & Chief Medical Officer Former FDA medical officer Simcha Rock, CPA, MBA Chief Financial Officer Former Senior VP Edmond de Rothschild Gil Ben - Menachem, Ph.D., MBA Vice President, Business Development Formerly at Paramount, Teva, Dexcel, NIH Hadas Reuveni, Ph.D. Founder & Chief Technology Officer - TyrNovo Formerly at Keryx (NASDAQ: KERX) Isaac Israel Chief Executive Officer Former CEO of BeeContact (TASE: BCNT), NextGen Biomed (TASE: NXGN)

Pipeline ϱ Drug Therapeutic Field Preclinical Phase I/II Phase III Submission Approval KIT - 302 Osteoarthritis pain and hypertension NT - 219 Oncology PDUFA target date: May 31 , 2018 ϱ

About KIT - 302 • KIT - 302 's pivotal Phase III trial successfully met its primary efficacy endpoint - announced in December 2015 . Data showed that KIT - 302 is more effective at lowering blood pressure than amlodipine alone • Formulated with 200 mg celecoxib and three different dosages ( 2.5 , 5 , 10 mg) of amlodipine • Regulatory submission path with U.S. FDA is under a Special Protocol Assessment (SPA) and 505 (b) 2 route • KIT - 302 NDA was submitted to and filed by FDA. PDUFA date expected on May 31 , 2018 ϲ Simultaneous treatment of osteoarthritic pain and blood pressure elevation Fixed dose combination of Celecoxib , a COX - 2 selective NSAID (the active ingredient in Pfizer’s Celebrex®) + Amlodipine, a blood pressure - lowering agent (a calcium channel blocker) (the active ingredient in Pfizer's Norvasc®) *Celebrex® is a registered trademark of G.D. Searle LLC (a subsidiary of Pfizer Inc.). Norvasc® is a registered trademark of Pfizer Inc.

Medical Rationale ϳ Celecoxib (the active ingredient in Pfizer's Celebrex®) • The only widely prescribed selective COX - 2 NSAID approved in the US (unlike non - selective NSAIDs, celecoxib carries limited gastrointestinal risks) • Since 2005 , has an FDA - mandated “black box” label warning of increased cardiovascular risks • According to FDA, cardiovascular risks can occur as early as the first few weeks of using an NSAID, and may increase with longer use Amlodipine ( the active ingredient in Pfizer's Norvasc®) • Calcium channel blocker ; anti - hypertensive • Unlike other blood pressure - lowering drug groups – such as diuretics, ACE inhibitors, and angiotensin II receptor antagonists – calcium channel blockers do not cause deterioration of renal function, including possible acute renal failure* * The FDA Safety Information and Adverse Event Reporting Program; http://www.fda.gov/Safety/MedWatch/SafetyInformation/ucm 270998 .htm

KIT - 302 Phase III Trial Design (under Special Protocol Assessment from FDA) Demonstrate that the reduction in blood pressure in the KIT - 302 arm is at least 50 % of the reduction in the amlodipine arm Measurement of pain was not required by FDA Primary endpoint ϴ Newly diagnosed hypertensive patients Celecoxib 200 mg + Amlodipine 10 mg AMLODIPINE 10 mg CELECOXIB 200 mg PLACEBO Data Collection and Statistical Analysis Double - blind, placebo - controlled, multi - center study N = 152 4 - arm trial with 30 - 45 patients in each arm 2 weeks of treatment KIT - 302

KIT - 302 Phase III Trial Results • Primary efficacy endpoint was successfully achieved (P= 0.001 ) • Demonstrated 2.5 x better blood pressure reduction than FDA requirement ( 50 % of amlodipine arm) • Demonstrated consistent reduction in all measures of blood pressure • Observed beneficial renal functions: • Additional clinical trial to scientifically validate the renal benefits (not required for NDA submission) was completed. Topline results were announced in October, 2017 ϵ * Error bars – standard error of mean Blood Pressure Reduction of KIT - 302 vs. Amlodipine and Celecoxib* KIT - 302 demonstrated even better BP reduction than same amount of amlodipine given without celecoxib Measure KIT - 302 Amlodipine Creatinine plasma level reduction - 3.22 μ mol/L - 2.55 μ mol/L Peripheral edema (% patients) 8.2 % 15.6%

KIT - 302 Second Phase III/IV Trial Design ϭϬ Hypertensive patients (following a wash - out period) Celecoxib 200 mg + Amlodipine 10 mg AMLODIPINE 10 mg CELECOXIB 200 mg PLACEBO Data Collection and Statistical Analysis Double - blind, placebo - controlled, multi - center study N = 1 Ϭ 2 3 - arm trial 2 weeks of treatment KIT - 302 Demonstrate that the reduction in blood pressure in the KIT - 302 arm is at least 50 % of the reduction in the amlodipine arm Improvements of renal function measurements Primary endpoint Secondary endpoints

KIT - 302 Second Phase III/IV Trial Results ϭϭ • Primary efficacy endpoint successfully met (p= 0.019 ), thus first Phase III trial results validated • Statistically significant reduction of serum creatinine observed vs. baseline • KIT - 302 enhanced the creatinine reduction by an average of 102 % vs. amlodipine alone • KIT - 302 demonstrated systolic blood - pressure reduction comparable to amlodipine • Completion and submission of the report to FDA expected by January 2018 KIT - 302 (n=48) Amlodipine (n=49) Creatinine plasma level reduction - 3.48 μ mol/L - 1.72 μ mol/L p - value 0.0005 0.075

KIT - 302 US Target Markets ϭϮ KIT - 302 targets osteoarthritic patients currently treated with NSAIDs (celecoxib as well as others) who also suffer from existing or newly diagnosed hypertension OSTEOARTHRITIS 50 million patients* NSAIDs 60 % of all OA Rxs * Arthritis Foundation: http://www.arthritis.org/ ** Hypertension Among Adults in the United States: National Health and Nutrition Examination Survey, 2011 – 2012 ARTHRITIS PREVALENCE* • More than 50 million adults in the US have doctor - diagnosed osteoarthritis • 67 million people are expected to have doctor - diagnosed osteoarthritis by 2030 HYPERTENSION PREVALENCE** • 29 % of US adults older than 18 • 65 % of US adults older than 60 COMORBIDITIES • 44 % of adults with high blood pressure have osteoarthritis** HYPERTENSION Celecoxib 24 % of all NSAIDs KIT - 302

KIT - 302 Benefits All Stakeholders ϭϯ KIT - 302 KIT - 302 is expected to be the only NSAID whose labeling will indicate reduction of blood pressure and consequent risk reduction of heart attack, stroke and death • Treats two conditions simultaneously • Increases convenience (one pill instead of two) • Lowers co - pay Patients Physicians • Improves patient compliance • Reduces concerns related to NSAID side effects Payors • Lowers disease burden • Improves patient health • Lowers overall healthcare costs

KIT - 302 Commercialization ϭϰ South Korea - Exclusively licensed to Kuhnil Pharmaceuticals (March 2017 ) Ongoing partnership discussions in the US and EU

Pipeline ϭϱ Drug Therapeutic Field Preclinical Phase I/II Phase III Submission Approval KIT - 302 Osteoarthritis pain and hypertension NT - 219 Oncology PDUFA target date: May 31 , 2018 ϭϱ

ϭϲ NT - 219 : Overcoming Cancer Drug Resistance • Recently acquired majority ( 92 %*) shares in privately held TyrNovo Ltd. • TyrNovo develops NT - 219 , a first - in - class small molecule that prevents, reverses, and delays resistance to anti - cancer drugs • Dual inhibitor of STAT 3 and IRS 1 / 2 : two signal pathways associated with drug resistance • Demonstrated outstanding efficacy in patient - derived xenograft (PDX) models • Favorable response received from FDA in a pre - IND meeting • Preclinical work ongoing; IND expected in 12 - 18 months • Initial clinical trial expected in pancreatic cancer patients in combination with gemcitabine (Gemzar®) • Long - term strategy to develop NT - 219 , in combination with other oncology drugs for additional indications, in collaboration with strategic partners who have expressed solid preliminary interest in the drug *including 27 % contracted, pending closing

NT - 219 : Mechanism of Action • Anti - cancer drugs induce activation of two feedback pathways, STAT 3 and IRS, leading to drug resistance • NT - 219 simultaneously targets STAT 3 and IRS 1 / 2 , thereby overcoming drug resistance and extending the positive response to the drugs • Inhibition of STAT 3 may also activate anti - cancer immunity 17

NT - 219 Prevents Acquired Resistance to EGFR Inhibitor (Tarceva®) in Head and Neck Cancer Results in PDX Models When administered in combination with Tarceva®, no resistance was developed 18

NT - 219 Reverses Existing Resistance to Tarceva® in Head and Neck Tumors Results in PDX Models (cont’d) When administered after development of resistance, NT - 219 reversed resistant tumors to sensitive 19

NT - 219 Delays Recurrence of Tumors of Head and Neck with Cetuximab Results in PDX Models (cont’d) Tumors treated with NT - 219 and Cetuximab took much longer to develop following treatment discontinuation 20

Results in PDX Models (cont’d) 21 When administered in combination with Mekinist® (Trametinib), a prolonged effect was observed ) 3 Tumor volume (mm NT - 219 Prevents Acquired Resistance to MEK Inhibitor (Mekinist®) in Mutated - BRAF Anaplastic Thyroid Cancer

NT - 219 Converts Non - Responding Tumors to Keytruda® to Responders in Humanized PDX of Esophagus Cancer Double autologous model - tumors and PBMCs of the same patient Results in Immuno - Oncology PDX Model in Combination with Keytruda® 22

Summary of Demonstrated Efficacy TYPE DRUG (TRADE NAME) CANCER TYPE COMPANY Targeted Drugs Antibody Cetuximab (Erbitux ® ) Head and Neck Merck / Eli Lilly Cetuximab (Erbitux ® ) + FOLFOX/FOLFIRI Colon (wt KRAS) Kinase Inhibitors Erlotinib (Tarceva ® ) Head and Neck Roche / Astellas Afatinib (Giotrif ® ) Head and Neck Boehringer Ingelheim Osimertinib (Tagrisso ® ) Lung AstraZeneca Vemurafenib (Zelboraf ® ) Melanoma Roche Trametinib (Mekinist ® ) Thyroid Novartis Everolimus (Afinitor ® ) Uterine Adenosarcoma Novartis Chemotherapy Gemcitabine (Gemzar ® ) Pancreatic Eli Lilly 5FU, Oxaliplatin (FOLFOX) Colon Sanofi, Sun, Teva Docetaxel (Taxotere ® ) Prostate Sanofi Immunotherapy Antibody Pembrolizumab (Keytruda ® ) Melanoma, NSCLC, Head and Neck Merck and Co. NT- 219 will be developed in combination with approved oncology drugs to increase efficacy, expand target population, and extend treatment duration 23

Selection of First Indication • Genomic analysis of resistant tumors in the H&N model revealed amplification in KRAS and NF - 1 loss • Since KRAS mutation is associated with 95 % of pancreatic tumors, biopsies from four different pancreatic cancer patients were tested • Results demonstrated beneficial effect of NT - 219 in 4 / 4 biopsies • Based on these outstanding results, pancreatic cancer was selected as the first indication • A Phase I/II trial beginning in 2019 will test NT - 219 in combination with gemcitabine Ϯϰ

NT - 219 Converts Non - Responding Tumors to Responders to Gemcitabine in 4 / 4 PDX Models of Pancreatic Cancer Days Days 25 Days Days ) 3 Tumor volume (mm ) 3 Tumor volume (mm ) 3 Tumor volume (mm ) 3 Tumor volume (mm Expected Phase I/II Clinical Trial

Summary Proven management team • Management team with track record in drug development and regulatory expertise Balanced and diverse pipeline • Lead drug candidate KIT - 302 approval expected in May 2018 • NT - 219 IND submission expected in 12 - 18 months Large m arket potential • KIT - 302 addresses large target population • NT - 219 has blockbuster potential in multiple malignancies Strong IP portfolio • KIT - 302 is US patent protected through 2030 • NT - 219 composition patent was granted, combination patents are pending 26

Thank you Innovative Biopharmaceuticals Company Headquarters One Azrieli Center Round Tower, Floor 19 132 Begin Road Tel Aviv 670110 Israel US Medical Research Office 1615 Suter's Lane NW Washington DC 20007 Contact Us Email: Info@kitovpharma.com Info@tyrnovopharma.com www.kitovpharma.com www.TyrNovopharma.com Tel . 972 3 9333121 Fax . 972 3 5097196